At the Virtual 2020 ESMO Congress, Ana Carneiro talks about disparities in access to oncology trials from the last decade. The late-breaking abstract ‘Disparities in access to oncology clinical trials in Europe in the period 2009-2019‘ (LBA66) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- Prior to this study, what was already known about disparities in cancer care and clinical trials across Europe? (0:14)
- Could you tell us a little about the aims and design of this study on access to oncology trials? (0:46)
- What were the findings of this study? (1:20)
- What are the limitations impacting access in clinical trials across European countries? (1:58)
- What can be done to address these inequalities? (2:48)
Speaker Disclosure: Ana Carneiro has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Policy
Stefan Gijssels, Eureopean Cancer Summit 2020 – The Beating Cancer Plan
touchONCOLOGY means Stefan Gijssels at the European Cancer Summit 2020 to discuss the Beating Cancer Plan and key highlights and outcomes from this year’s meeting. Questions How do you expect the cancer burden in Europe to change in the coming years? What are the aims and main components of the Beating Cancer Plan? What initiatives […]
Françoise Meunier, European Cancer Summit 2020 – Financial Toxicity and the ‘Right to be Forgotten’
Dr Françoise Meunier, Vice President of the Federation of European Academies of Medicine, joins touchONCOLOGY to discuss financial toxicity in patients with cancer and progress made with the “Right to be Forgotten” resolution made at the European Cancer Summit in 2018. Questions What does the term ‘financial toxicity’ mean, and what does it mean for […]
Daniel Kelly, European Cancer Summit 2020 – HPV Action Network
touchONCOLOGY joins Prof. Daniel Kelly to discuss the aims and scope of the European Cancer Organisation HPV Action Network. Questions What are the aims of the HPV Action Network? How can HPV-associated cancers be reduced and why is this resolution important? Could you tell us about the European Cancer Organisation’s recent action plan and report, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!